Fig. 3

Mutational signature and chromosomal instability of different types of compound EGFR mutations. A The mutational signature analysis for patients with different types of compound EGFR mutations. Patients whose baseline tumor tissue samples were characterized by large panel targeted sequencing of 425 cancer-relevant genes were included in the analysis (n = 408). The contribution of each signature was the proportion of the selected signature over all the detected signatures in that specific patient. The Kruskal–Wallis test was conducted to compare multiple groups. The chromosomal instability score in patients with double vs multiple EGFR mutations (B) or in patients with different types of compound EGFR mutations (C). Patients whose baseline tumor tissue samples were characterized by large panel targeted sequencing of 425 cancer-relevant genes were included in the analysis (n = 408). P-value of < 0.05 was considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). CIS, chromosomal instability score